SS Innovations International Inc. Common Stock
SS Innovations International, Inc., together with its subsidiaries, operates as a commercial-stage surgical robotics company in India and internationally. It offers SSi Mantra, a surgical robotic system; and SSi Mudra, a range of stapling, energy, and core instrumentations for surgical systems. The company also develops NADI " Automated Coronary Anastomotic Connector, a micro stapling device; SSi Multi-Fire Clip Applier, a cartridge-based clip applicator; SSi Robotic Stapler; SSi Maya " XR Pre-Operative Simulator, a robotic surgery platform; SSi Holographic Anatomy, an augmented reality tool; SSi Chitrasa " Advanced DICOM Viewer, an AI enabled application viewer; and SSi Mixed Reality Headset, a medical-grade device. In addition, it offers instrument tips, including forceps, scissors, electrocautery tools, scalpels, and other surgical tools. Further, the company provides accessory products, such as sterile drapes, 3d stereo endoscopes, cannulas, and seals, as well as tele proctoring and telesurgery products. Additionally, it offers installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring services. The company sells its products through direct sales organizations and distributor networks. SS Innovations International, Inc. is headquartered in Gurugram, India.
Open SSII dashboard ↗Exagen Inc. Common Stock
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Open XGN dashboard ↗